Orris
attachment
attachment

Pregnancy of 30 weeks with itching over this area management

Reading File
The image shows a swollen foot/ankle (pedal edema) in a pregnant patient at 30 weeks with itching. The key diagnosis to consider here is Intrahepatic Cholestasis of Pregnancy (ICP) — pruritus with pedal edema at 30 weeks is a classic presentation. Let me search the library and literature simultaneously.
Finding Sources
Searching PubMed

intrahepatic cholestasis pregnancy management

Reading File
Reading File
Reading File
Let me find the treatment/management section:
Reading File
Reading File
I now have comprehensive information from the textbook. Let me also get the earlier part of the management section that was truncated:
Reading File
I now have all the information needed for a comprehensive answer.

Clinical Assessment

The image shows pedal edema (swollen foot and ankle). In the context of 30 weeks pregnancy with pruritus over the feet, the leading diagnosis is:
Intrahepatic Cholestasis of Pregnancy (ICP) — pruritus is classically felt on the palms and soles but can affect any body part, including the feet/ankles.

Diagnosis — First Steps

InvestigationWhat to look for
Serum bile acids>10 μmol/L = diagnostic; >40 μmol/L = severe
LFTs (AST, ALT, bilirubin, GGT)Elevated transaminases (may precede bile acid rise by weeks)
Liver ultrasoundExclude biliary obstruction, gallstones
Hepatitis C serology, ANARule out concurrent hepatitis C, autoimmune hepatitis
Repeat tests in 1–2 weeks if normal but pruritus persistsBiochemical changes may lag symptoms
Note: ICP does not cause a primary skin rash — excoriations from scratching may simulate one. Pedal edema is a common accompaniment in late pregnancy.

Management

1. Pharmacological (Maternal symptoms)

Ursodeoxycholic acid (UDCA) — first-line, only drug with consistent evidence:
  • Dose: 10–15 mg/kg/day, started at 500 mg twice daily
  • May increase up to 2000 mg/day if needed
  • Reduces pruritus, AST, ALT, bilirubin, and bile acid levels
  • Most effective when bile acids >40 μmol/L
  • Also reduces bile acid levels in cord blood and amniotic fluid, likely reducing fetal risk
Second-line / adjuncts (less evidence):
  • Topical aqueous cream with menthol — symptom relief only
  • Cholestyramine — anion exchange resin; less effective
  • Dexamethasone, S-adenosylmethionine, guar gum — evidence weaker than UDCA
  • Rifampicin, opiate antagonists, ondansetron, phototherapy — used for cholestasis-related pruritus in non-pregnant patients; limited data in ICP

2. Fetal Monitoring

Fetal ConcernAction
Spontaneous preterm laborVigilant monitoring
Fetal asphyxia, meconium stainingAntenatal surveillance (NST, BPP) — though no evidence these definitively prevent stillbirth
Sudden fetal death (bile acid-induced arrhythmia)Heightened awareness; delivery planning
  • Fetal risks are highest when bile acids >40 μmol/L (asphyxia, meconium, preterm)
  • Stillbirth risk is significantly elevated only at >100 μmol/L

3. Timing of Delivery

  • Early delivery is the only intervention that reduces stillbirth risk
  • Standard practice: induce labor at 37 weeks (or earlier if severe disease)
  • At 30 weeks: continue pregnancy with close monitoring, UDCA, and serial bile acid levels
  • If bile acids escalate to >100 μmol/L or fetal compromise occurs → expedite delivery balancing prematurity risks

4. Counseling

  • Recurrence rate in future pregnancies: 40–90%
  • Avoid cholestatic antibiotics (erythromycin, flucloxacillin, amoxicillin-clavulanic acid) in future
  • Hormonal contraception carries a ~10% risk of pruritus/hepatic impairment in affected women

Summary Algorithm at 30 Weeks

Pruritus + foot swelling at 30 wks
         ↓
Serum bile acids + LFTs + liver USS
         ↓
Bile acids >10 µmol/L → ICP confirmed
         ↓
Start UDCA 500 mg BD (titrate to 10–15 mg/kg/day)
         ↓
Serial bile acid levels q1–2 weeks
         ↓
Antenatal surveillance (NST/BPP)
         ↓
Plan delivery at 37 weeks (or earlier if severe)
Sources: Creasy & Resnik's Maternal-Fetal Medicine, 9th ed., pp. 1582–1584; systematic review [PMID: 39093046] confirms severity-dependent fetal risk.
This is a shared conversation. Sign in to Orris to start your own chat.